Business Context and Reporting Period
This Form 8-K Current Report from TriSalus Life Sciences, Inc. (TLSI) covers events occurring on July 24, 2025. The filing details the final results of an Offer to Exchange and a Consent Solicitation regarding the Company's Series A Convertible Preferred Stock.
Key Financial Metrics
This filing is a current report regarding corporate governance and capital structure changes. It does not provide financial performance data such as revenue, profit, cash flow, margins, debt levels, or liquidity metrics. The filing text does not provide a clear value for these items.
Material Changes
- Offer Results: The Offer to Exchange Series A Convertible Preferred Stock for Common Stock expired on July 23, 2025. The Company received valid tenders for 3,551,502 shares of Preferred Stock, representing approximately 98.82% of the outstanding shares.
- Consent Solicitation: The Company received the requisite approval (exceeding the majority threshold) to amend the Certificate of Designations for the Preferred Stock.
- Amendment Filing: On July 24, 2025, the Company filed the Preferred Stock Amendment with the Delaware Secretary of State. This amendment permits the Company to require the conversion of all outstanding Preferred Stock into Common Stock based on the Exchanged Value divided by the Conversion Price.
- Settlement Timeline: The Company expects to accept all validly tendered shares for exchange and settlement on or before August 1, 2025.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future financial performance, or specific risk factors beyond the standard incorporation of the amendment terms. The primary contingency noted is the satisfaction or waiver of conditions described in the Prospectus/Offer to Exchange, which the Company indicates have been met given the high tender rate and consent approval.
Investor Verification Checklist
- Verify the final settlement date of the Preferred Stock exchange (expected on or before August 1, 2025).
- Review the specific terms of the "Conversion Price" and "Exchanged Value" as defined in the amended Certificate of Designations (Exhibit 3.1) to calculate the exact number of Common Stock shares to be issued.
- Confirm the impact of the 98.82% tender rate on the Company's capital structure and potential dilution to existing Common Stock holders.
- Check for any remaining conditions to the Offer that were not explicitly waived in the filing.